Last reviewed · How we verify
CHF 5993 200/6/12.5 µg
CHF 5993 is a triple-combination inhaled therapy that combines a long-acting beta-2 agonist, long-acting muscarinic antagonist, and inhaled corticosteroid to improve airway function and reduce inflammation in chronic obstructive pulmonary disease.
CHF 5993 is a triple-combination inhaled therapy that combines a long-acting beta-2 agonist, long-acting muscarinic antagonist, and inhaled corticosteroid to improve airway function and reduce inflammation in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | CHF 5993 200/6/12.5 µg |
|---|---|
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Triple combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) |
| Target | Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
The formulation delivers beclomethasone (ICS), formoterol (LABA), and glycopyrronium (LAMA) in a single inhaler. The LABA and LAMA work synergistically to relax airway smooth muscle through different mechanisms, while the ICS reduces airway inflammation. This triple therapy addresses multiple pathophysiological mechanisms in COPD to improve lung function and reduce exacerbations.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Cough
Key clinical trials
- Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR® (PHASE1)
- PK of BDP/FF/GB Single-inhaler Triple Therapy in Japanese vs. Caucasians (PHASE1)
- TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER) (PHASE3)
- Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHF 5993 200/6/12.5 µg CI brief — competitive landscape report
- CHF 5993 200/6/12.5 µg updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI